Loading clinical trials...

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

NCT01471106•M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

The goal of this clinical research study is to learn if dasatinib can help prevent breast cancer from developing in the unaffected breast. Dasatinib is designed to decrease the activity of one or more proteins that are responsible for the uncontrolled growth of tumor cells. This is an investigational study. Dasatinib is FDA approved and commercially available for the treatment of leukemia. Its use in breast cancer patients in investigational. Up to 66 patients will take part in this multicenter study. Up to 60 will be enrolled at MD Anderson.

Detailed Description

Study Drug Administration: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 3 study groups: * If you are in Group 1, you will take dasatinib 40mg once a day by mouth with water. * If you are in Group 2, you will take dasatinib 80mg once a day by mouth with water. * If you are in Group 3, you will not receive dasatinib. You will be given a study drug diary to complete. In the diary, you will record when you take the study drug. Study Visits: At Month 1: * You will be called by a nurse and asked about any drugs you are taking and side effects you may be having. * You will be asked about any drugs you may be taking and side effects you may be having. * Your drug diary will be reviewed. At Month 2 you will be called by a nurse and asked about any drugs you are taking and side effects you may be having. You will also be asked to review your drug diary. This call will take about 20 minutes At Month 3 (or if you leave the study early): * You will have a fine needle aspirate (FNA) of the breast for biomarker testing. Biomarkers are found in the blood/tissue and may be related to your reaction to the study drug. * Blood (about 2-3 tablespoons) will be drawn for biomarker testing. * You will be asked about any drugs you may be taking and side effects you may be having. * Your drug diary will be reviewed. Length of Study: You may remain on study for up to 3 months. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Histological confirmation of ER negative breast carcinoma (defined as less than 10%), stage I, II, or III
•2. Completed all adjuvant therapy including (if indicated) endocrine, trastuzumab, radiation therapy
•3. At least 18 years of age.
•4. Female: A female is eligible to enter and participate in the study if she is of: a. Non-childbearing potential (i.e., women with functioning ovaries who have a current documented tubal ligation, hysterectomy alone, hysterectomy and bilateral salpingo-oophorectomy, bilateral salpingo-oophorectomy alone or women who are post-menopausal); or b. Childbearing potential (i.e., women with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility. This category includes women with oligomenorrhoea (severe), women who are perimenopausal, and young women who have begun to menstruate), has a negative serum pregnancy test at screening, and agrees to one of the following where considered acceptable to the local IRB/IEC: • Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm).
•5. (Continued from above) • Abstinence from sexual intercourse from 2 weeks prior to administration of the investigational product, throughout the active study treatment period. • Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject. • Any intrauterine device (IUD). • Barrier methods including diaphragm or condom with a spermicide.
•6. Able to swallow and retain oral medication.
•7. ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2.
•8. Provided written informed consent.
•9. Adequate bone marrow function: Hemoglobin \>/= 9 gm/dL. • Absolute granulocyte count \>/= 1,500/mm\^3 (1.5 x 10\^9/L). • Platelets \>/= 75,000/mm\^3 (100 x 10\^9/L).
•10. Serum creatinine \< 1.4 mg/dL or calculated creatinine clearance (CrCl) \>/= 30 mL/min
+4 more criteria

Exclusion Criteria

•1. Unwillingness to undergo RPFNA.
•2. Contraindication to RPFNA including breast implant(s), bilateral radiation, anticoagulation (excluding those on 81mg aspirin).
•3. Concurrent medical condition that would increase drug toxicity: Pleural or pericardial effusion, coagulation or platelet function disorder, ongoing or recent (less than 3 months gastrointestinal bleeding)
•4. Uncontrolled angina, congestive heart failure, MI (within last 6 months), congenital long QT syndrome, history of clinically significant ventricular arrhythmia, prolonged QTcF interval on pre-entry EKG (greater than normal range)
•5. Hypokalemia or hypomagnesemia if it cannot be corrected
•6. Is a pregnant or lactating female.
•7. Has evidence of recurrent or metastatic (Stage IV) breast cancer.
•8. Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations.
•9. Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dasatinib
•10. Has received treatment with any investigational drug in the previous 4 weeks.
+4 more criteria

Locations (2)

Duke University

Durham, North Carolina, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

January 21, 2014

Primary Completion Date

January 31, 2024

Completion Date

May 30, 2024

Last Updated

July 10, 2024

Enrollment

ACTUAL participants

Conditions

Breast Cancer

Interventions

Dasatinib

DRUG

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 10, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Inclusion Criteria

Exclusion Criteria

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer